Known targets — ChEMBL curated mechanism
CHRM1DRD2DRD3DRD4HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR2APDE3ASIGMAR1
The experimentally established mechanism targets of Lactic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lactic Acid SCHEMBL4755238 | 1.00 | TP53 (0.69) | TP53CA1CA4CA2TSHR | |
| Lactic Acid SCHEMBL27558092 | 0.94 | TP53 (0.69) | TP53CA1CA4TSHRFFAR3 | |
| Lactic Acid SCHEMBL25402793 | 0.94 | TP53 (0.69) | TP53CA1CA4TSHRFFAR3 | |
| Lactic Acid SCHEMBL27980401 | 0.90 | TP53 (0.73) | TP53CA1CA4CA2TSHR | |
| L-Lactic Acid SCHEMBL29389969 | 0.90 | TP53 (0.73) | TP53CA1CA4CA2TSHR | |
| Lactic Acid SCHEMBL29020056 | 0.90 | TP53 (0.73) | TP53CA1CA4CA2TSHR | |
| Lactic Acid SCHEMBL8024518 | 0.88 | TP53 (0.69) | TP53CA1CA4CA2TSHR | |
| Lactic Acid SCHEMBL264447 | 0.88 | TP53 (0.69) | TP53CA1CA4CA2TSHR | |
| Lactic Acid SCHEMBL15544221 | 0.88 | TP53 (0.69) | TP53CA1CA4CA2TSHR | |
| Lactic Acid SCHEMBL10320997 | 0.85 | TP53 (0.65) | TP53CA1CA4CA2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9254356-B2 | Dialysis system for preparing a citrate dialysate from a base concentrate and an acid concentrate | BAXTER INTERNATIONAL INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-20140319030-A1 | Citrate-Based Dialysate Chemical Formulations | BAXTER INTERNATIONAL INC. | 2014-10-30 | — | — | US | disclosed |
| US-8828232-B2 | Citrate-based dialysate chemical formulations | BAXTER INTERNATIONAL INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20130248448-A1 | Citrate-Based Dialysate Chemical Formulations | BAXTER HEALTHCARE S.A. | 2013-09-26 | — | — | US | disclosed |
| US-8414768-B2 | Citrate-based dialysate chemical formulations | BAXTER INTERNATIONAL INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120291875-A1 | Citrate-Based Dialysate Chemical Formulations | BAXTER HEALTHCARE S.A. (CH) | 2012-11-22 | — | — | US | disclosed |
| US-8202547-B2 | Citrate-based dialysate chemical formulations | BAXTER INTERNATIONAL INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20110171271-A1 | Citrate-Based Dialysate Chemical Formulations | HHD LLC (US) | 2011-07-14 | — | — | US | disclosed |
| US-7883725-B2 | Citrate-based dialysate chemical formulations | HHD LLC (US) | 2011-02-08 | — | — | US | disclosed |
| US-20090274774-A1 | Citrate-Based Dialysate Chemical Formulations | HHD LLC (US) | 2009-11-05 | — | — | US | disclosed |
| US-7544301-B2 | Comprise liquid or dry acid concentrate unit stored in first vessel, and liquid or dry citrate-containing bicarbonate concentrate unit stored in second vessel; contents of first and second vessels are emptied into dialysate preparation tank and mixed with water to form batch of dialysate | HHD LLC (US) | 2009-06-09 | — | — | US | disclosed |
| US-20060037910-A1 | Comprise liquid or dry acid concentrate unit stored in first vessel, and liquid or dry citrate-containing bicarbonate concentrate unit stored in second vessel; contents of first and second vessels are emptied into dialysate preparation tank and mixed with water to form batch of dialysate | AKSYS LTD. (US) | 2006-02-23 | — | — | US | disclosed |